|Back Zoom + Zoom -|
Nomura in its report predicted CSPC PHARMA (01093.HK) to have delivered FY20 revenue and drug sales of RMB25.7 billion and RMB21.3 billion, implying respective growth of 21% and 23% in 4Q20.
The broker retained Buy on CSPC PHARMA at the target price $12, trimmed from $19.83.
AAStocks Financial News
Web Site: www.aastocks.com